These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34059612)

  • 21. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society.
    Napoli R; Avogaro A; Formoso G; Piro S; Purrello F; Targher G; Consoli A
    Nutr Metab Cardiovasc Dis; 2021 Nov; 31(12):3257-3270. PubMed ID: 34627692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Adams LA; Anstee QM; Tilg H; Targher G
    Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease.
    Ismaiel A; Dumitrascu DL
    Am J Ther; 2023 May; 30(3):e242-e256. PubMed ID: 32467498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
    Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
    Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular risk factors in non-alcoholic fatty liver disease.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Askling J; Hultcrantz R; Kechagias S
    Liver Int; 2019 Jan; 39(1):197-204. PubMed ID: 30253056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.
    Hassen G; Singh A; Belete G; Jain N; De la Hoz I; Camacho-Leon GP; Dargie NK; Carrera KG; Alemu T; Jhaveri S; Solomon N
    Cureus; 2022 May; 14(5):e25495. PubMed ID: 35783879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
    Tsankof A; Neokosmidis G; Koureta E; Veneti S; Cholongitas E; Tziomalos K
    Front Endocrinol (Lausanne); 2022; 13():984041. PubMed ID: 36120448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
    Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
    Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms.
    Møller S; Kimer N; Kronborg T; Grandt J; Hove JD; Barløse M; Gluud LL
    Semin Liver Dis; 2021 Aug; 41(3):235-247. PubMed ID: 33992031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes.
    Mantovani A; Mingolla L; Rigolon R; Pichiri I; Cavalieri V; Zoppini G; Lippi G; Bonora E; Targher G
    Int J Cardiol; 2016 Dec; 225():387-391. PubMed ID: 27768965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
    Muzurović E; Mikhailidis DP; Mantzoros C
    Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pancreatic steatosis and iron overload increases cardiovascular risk in non-alcoholic fatty liver disease.
    Marti-Aguado D; Ten-Esteve A; Baracaldo-Silva CM; Crespo A; Coello E; Merino-Murgui V; Fernandez-Paton M; Alfaro-Cervello C; Sánchez-Martín A; Bauza M; Jimenez-Pastor A; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández A; Aguilera V; Latorre M; Monton C; Escudero-García D; Bosch-Roig I; Alberich-Bayarri Á; Marti-Bonmati L
    Front Endocrinol (Lausanne); 2023; 14():1213441. PubMed ID: 37600695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NAFLD: a multisystem disease.
    Byrne CD; Targher G
    J Hepatol; 2015 Apr; 62(1 Suppl):S47-64. PubMed ID: 25920090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.
    van den Berg EH; Wolters AAB; Dullaart RPF; Moshage H; Zurakowski D; de Meijer VE; Blokzijl H
    Liver Int; 2019 Jul; 39(7):1343-1354. PubMed ID: 30968536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liver Stiffness Severity is Associated With Increased Cardiovascular Risk in Patients With Type 2 Diabetes.
    Mangla N; Ajmera VH; Caussy C; Sirlin C; Brouha S; Bajwa-Dulai S; Madamba E; Bettencourt R; Richards L; Loomba R
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):744-746.e1. PubMed ID: 31100460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV.
    Lonardo A; Ballestri S; Guaraldi G; Nascimbeni F; Romagnoli D; Zona S; Targher G
    World J Gastroenterol; 2016 Nov; 22(44):9674-9693. PubMed ID: 27956792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.